Check out highlights from news published on day 1 of CHEST 2026, spanning asthma, COPD, bronchiectasis, pulmonary rehabilitation, and fibrotic ILD.
Commentary|Videos|June 4, 2026
HCPLive Five: Asthma Updates at ATS 2026
Fact checked by: Chelsie Derman
5 interviews. 5 minutes. The asthma data from ATS 2026 your patients will be asking about.
Advertisement
Advertisement
Related to this article
Catch up on any data and key clinician perspectives presented at the Heart Failure Society of America Annual Scientific Meeting 2026.
Chronic proton pump inhibitor use carried 60% greater odds of asthma exacerbation and nearly 4-fold odds of rescue corticosteroid use in a matched cohort of 2456 patients.
A new analysis of 4 major trials has revealed the association between lower SBP and higher TTR and the risk of recurrent stroke after intracerebral hemorrhage.
Data from the phase 2a BIRCH trial demonstrated the treatment’s improvements in mRS and NLR, positioning it for a late-phase trial in the future.
A new analysis of the BRIDGE-TNK trial has demonstrated that patients with cardioembolism are more likely to derive benefit than those with large artery atherosclerosis.
Check out highlights from news published on day 3 of CHEST 2026, spanning COPD, pulmonary embolism, pulmonary hypertension, and AI.
At CHEST 2026, Retno Ariza Soemarwoto, MD, discusses curcumin’s effect on IL-17 in COPD, bioavailability, and what a guideline-ready trial needs.
Advertisement
Advertisement